Monitor for any upcoming earnings releases or clinical trial updates that may have prompted this timing; consider whether this reflects routine portfolio management or a signal of reduced confidence ahead of potential negative catalysts.
Price Chart
Executive Summary
Three executive insiders at Xenon Pharmaceuticals (XENE) sold shares worth over $550K in open-market transactions within a 2-day window, following the exercise of stock options. The sales represent a coordinated monetization of equity compensation, with the CEO accounting for over 70% of the total value sold.
Key Financial Metrics
Key Facts
- CEO Ian Mortimer sold $403,584 worth of shares in a single open-market transaction on March 13, 2026.
- Chief Legal Officer and Chief Medical Officer sold $74,112 and $77,867 respectively on March 13.
- All three executives exercised stock options (totaling 37,500 shares) on March 12 at $0 cost, immediately preceding the sales.
- Total open-market sales: $555,563 across 10,060 shares at $55.225 per share.
- Sales represent approximately 0.011% of XENE's $4.8B market cap — small in relative terms but concentrated among top executives.
Financial Impact
$555,563 in insider selling from option exercises and open-market dispositions
Risk Factors
- Perception of insider pessimism due to coordinated timing among C-suite executives.
- Potential for short-term downward pressure on share price due to sentiment impact despite modest dollar volume.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (9 trades, 7d window) | cluster-XENE-1773447432169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 2, 2026 13w ago | Press Release | $60.96 $64.19 | ▲ +5.30% | ▲ +5.71% | $38.02 (−37.63%) |
Jun 5, 2026 17w ago | 144 | $51.21 $60.54 | ▲ +18.22% | ▲ +16.59% | $38.02 (−25.76%) |
Jun 3, 2026 17w ago | 8-K | $52.99 $60.96 | ▲ +15.04% | ▲ +16.41% | $38.02 (−28.25%) |
May 7, 2026 21w ago | Press Release | $56.44 $51.73 | ▼ −8.35% | ▼ −8.37% | $38.02 (−32.64%) |
Apr 22, 2026 23w ago | DEFA14A | $55.41 $54.68 | ▼ −1.32% | ▼ −5.95% | $38.02 (−31.38%) |
Apr 19, 2026 23w ago | Press Release | $57.09 $53.71 | ▼ −5.92% | ▼ −10.12% | $38.02 (−33.40%) |
Apr 15, 2026 24w ago | Press Release | $58.88 $55.00 | ▲ +6.59% | ▲ +12.63% | $38.02 (+35.43%) |
Apr 13, 2026 24w ago | 8-K | $59.35 $55.78 | ▼ −6.02% | ▼ −12.31% | $38.02 (−35.94%) |
Apr 7, 2026 25w ago | Press Release | $57.65 $57.40 | ▲ +0.43% | ▲ +10.21% | $38.02 (+34.05%) |
Mar 13, 2026 29w ago | Insider Cluster | $55.23 $58.60 | ▼ −6.10% | ▼ −2.51% | $38.02 (+31.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access